Scott Clarke

Scott Clarke brings with him more than 25 years of experience in the biotechnology and pharmaceutical industry.

He currently is the CEO of Ambagon Therapeutics, and serves on the board of Trishula Therapeutics, where he had been CEO. Prior to his role at Trishula, Scott was CEO of Tizona Therapeutics. Under his leadership, Tizona’s two lead programs advanced into the clinic, and the company built out its preclinical portfolio, culminating in the spinout of Tizona’s lead program into Trishula and Gilead’s acquisition of rights to the rest of Tizona’s pipeline for $300 million up front and $1.25 billion in milestones.

Prior to Tizona, Scott was the Global Head of Oncology Partnering and Head of Asia and Emerging Markets Partnering at Roche. In this role, he oversaw licensing, clinical collaborations, and acquisitions in oncology, and he was also responsible for sourcing opportunities across all indications from Asia.

Earlier in his career, Scott held multiple roles at BioMarin, including the Senior Vice President of Product Development, responsible for advancing its portfolio of clinical and late preclinical product candidates through approval. Before that, Scott was Vice President of Business Development and Scientific Licensing, overseeing all preclinical and early clinical licensing, and M&A.

Scott earned a BS in Chemical Engineering from the University of California, Berkeley, a MSc in Biotechnology at Northwestern University, and an MBA from London Business School.